[1] Fletcher C D M, Bridge J A, Hogendoorn P, et al.World Health Organization Classification of Tumours of Soft tissue and Bone[M]//Pathology and Genetics.Lyon:IARC Press, 2013:80-82.
[2] Stacchiotti S, Van Tine B A.Synovial sarcoma:current concepts and future perspectives[J].J Clin Oncol, 2018, 36(2):180-187.
[3] Vlenterie M, Ho V K, Kaal S E, et al.Age as anindependent prognostic factor for survival of localized synovial sarcoma patients[J].Br J Cancer, 2015, 113(11):1602-1606.
[4] Von Mehren M, Randall R L, Benjamin R S, et al.Soft tissue sarcoma, version 2.2016, NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw, 2016, 14(6):758-786.
[5] 倪鑫, 马晓莉, 王焕民.等.儿童及青少年非横纹肌肉瘤类软组织肉瘤诊疗规范(2019年版)[EB/OL].(2019-09-30)/[2019-10-20].http://www.nhc.gov.cn/yzygj/s3593/201909/5f1d3329606e4cd2aa6e 501603703ee4.shtml?from=timeline&isappinstalled=0&Ug5zWxtDmi=1569819968282.
[6] Brennan M F, Singer S, Maki R G, et al.Soft tissue sarcoma[M].In:DeVita V T, Hellmann S, Rosenberg S A, eds.Cancer principles and practice of oncology.8th ed.Philadelphia, PA:Lippincott Williams & Wilkins; 2008:1741-1794.
[7] 李斯文,王珊,汤静燕,等.儿童滑膜肉瘤多中心33例临床分析[J].中华小儿外科杂志,2019,40(2):97-102.
[8] 周锦桃,陈刚,叶伶.原发性肺血管滑膜肉瘤致肺栓塞一例报告[J].中华肿瘤防治杂志,2018,25(13):976-978.
[9] 高天,余铃,李舒,等.Notch信号通路促进滑膜肉瘤细胞SW982增殖和侵袭的研究[J].中国医科大学学报,2019,48(3):210-215.
[10] Radhakrishnan V, Dhanushkodi M, Narayanswamy K, et a1.Synovial sarcoma of kidney in a child:A rare presentation[J].J Indian Assoc Pediatr Surg, 2016, 2l(2):75-77.
[11] Veshti A, Prifti E M, Ikonomi M.Primary cardiac synovial sarcoma originating from the mitral valve causing left ventricular outflow tract obstruction[J].Heart Surg Forum, 2015, 18(3):650-653.
[12] Ferrari A, Chi Y Y, De Salvo G L, et al.Surgery alone is sufficient therapy for children and adolescents with low-risk synovial sarcoma:A joint analysis from the European Paediatric Soft Tissue Sarcoma Study Group and the Children's Oncology Group[J].Eur J Cancer, 2017, 78:1-6.
[13] Bagley A F, Grosshans D R, Philip N V, et al.Efficacy of proton therapy in children with high-risk and locally recurrent neuroblastoma[J].J Pediatr Blood Cancer, 2019, 66(8):e27786.
[14] Vlenterie M, Litiere S, Rizzo E, et al.Outcome of chemotherapy in advanced synovial sarcoma patients:Review of 15 clinical trials from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark for studies in this entity[J].Eur J Cancer, 2016, 58:62-72.
[15] Gronchi A, Ferrari S, Quagliuolo V, et al.Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001):Aninternational, open-label, randomised, controlled,phase 3, multicentre trial[J].Lancet Oncol,2017, 18(6):812-822.
[16] Pollack S M, He Q, Yearley J H, et al.T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas[J].Cancer, 2017,123(17):3291-3304.
[17] Scheer M, Dantonello T, Hallmen E, et al.Synovial sarcoma recurrence in children and young adults[J].Ann Surg Oncol, 2016, 23(Suppl 5):618-626.
[18] 陶芳,王国文,韩秀鑫,等.95例滑膜肉瘤的综合治疗及预后影响因素[J].肿瘤防治研究,2019,46(6):519-525.
[19] Palmerini E, Staals E L, Alberghini M, et al.Synovial sarcoma:retrospective analysis of 250 patients treated at a single institution[J].Cancer, 2009, 115(13):2988-2998.
[20] Kubo T, Shimose S, Fujimori J, et al.Prognostic value of SS18-SSX fusion type in synovial sarcoma; systematic review and meta-analysis[J].Springerplus, 2015, 4:375.
[21] 刘燕飞,贾超,张朦,等.儿童滑膜肉瘤12例临床病理学分析[J].中华病理学杂志,2019,48(9):705-709. |
